Safety and Efficacy Study of Correcting Hyperglycemia in Patients With Diabetes Having Out-patient Surgery
Status:
Withdrawn
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety and efficacy of intravenous (IV)
administration of FDA approved regular human insulin and subcutaneous (SC) administration of
humalog, a rapid-acting insulin analog (a synthetic insulin), for correction of hyperglycemia
(high blood sugar) during the immediate preoperative period in patients with diabetes having
outpatient surgery at the Emory Ambulatory Surgical Center (ASC).
In this randomized controlled clinical trial patients with diabetes will be administered
corrective doses of IV regular insulin or SC humalog for preoperative hyperglycemia to
determine whether SC humalog results in improved intra and post-operative blood sugar
control.The most common current practice at Emory University in the ambulatory surgical
setting is IV administration of regular insulin for treatment of pre-operative hyperglycemia.
Subjects will not be paid for their participation and will be assured of treatment for their
hyperglycemia regardless of study participation.